Search

everythinglearnresearchcommunity

for

Search:↓

YAP and TAZ proteins are necessary for the development of two types of skin cancer.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Targeting EGFR may help reduce hair loss from chemotherapy.

KRT17 may be a new target for endometrial cancer treatment because it helps cancer cells move and form new blood vessels.

WNT10B is linked to cancer development and affects survival and disease progression in various cancers.

A specific gene mutation causes a severe skin disorder in a family.

NCSTN gene mutation causes abnormal skin cell differentiation and more inflammation, contributing to Hidradenitis Suppurativa.

Keratin 10 end domains may increase skin cancer risk by reducing cell death.

GLI1 might protect against the start of skin cancer and is not linked to cancer severity.

Targeting multiple pathways and understanding genetic mutations are crucial for effective melanoma therapy.

17β-estradiol lowers polyamine oxidase levels in breast cancer cells through estrogen receptor 2.

Keratins K6 and K16 are expressed more freely in regenerating mouse skin than K1 and K10.

The document concludes that understanding genetic mutations in the PI3K-AKT-mTOR pathway can lead to better diagnosis and treatment for certain genetic skin disorders.

The extracellular matrix affects where tumors can start in the body.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

K10 may not prevent tumors as previously thought and might increase benign tumor risk.

Truncated hHb1 keratin may play a role in breast cancer cell transformation.

WNT10A helps esophageal cancer cells spread and keep renewing themselves.

Increased ODC expression makes normally tumor-resistant mice more prone to tumor development.

Different types of skin cells have unique genetic markers that affect how likely they are to spread cancer.

Senescent fibroblasts can help start tumors in normal skin cells.

The risk of skin tumors becoming malignant depends on the specific skin cell type affected.

CEC levels may be a useful marker for predicting prostate cancer progression.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

Keratin 75 might be important in oral cancer progression.

Different types of skin gland tumors have unique genetic traits, which can guide personalized treatments.

High ornithine decarboxylase levels may lead to hair loss and cancer by increasing CK2 activity in the nucleus.

New markers and pathways have been found in skin tumors, helping better understand and diagnose them.

Erythematous papulopustular eruptions in cancer patients using EGFR inhibitors show specific skin changes that vary with severity and treatment type.